8-K: Merck Reports Q1 2026 Results, Raises Outlook

Merck & Co. announced first-quarter 2026 financial results, reporting $16.3 billion in worldwide sales and raising its full-year financial outlook.

Summary

• Merck & Co. reported first-quarter 2026 worldwide sales of $16.3 billion, a 5% increase (3% excluding foreign exchange) compared to the same period in 2025.
• The company experienced a GAAP loss per share of $1.72 and a non-GAAP loss per share of $1.28, both significantly impacted by a $3.62 per share charge related to the acquisition of Cidara Therapeutics, Inc.
• Key product growth drivers included KEYTRUDA/KEYTRUDA QLEX with $8.0 billion in sales (12% growth) and WINREVAIR with $525 million in sales (88% growth).
• Animal Health sales also saw a strong performance, increasing by 13% to $1.8 billion.
• Merck raised its full-year 2026 financial outlook, now expecting worldwide sales between $65.8 billion and $67.0 billion, and narrowing its expected non-GAAP EPS range to $5.04-$5.16.
• The company announced an agreement to acquire Terns Pharmaceuticals, Inc., which is expected to close in May and will result in a one-time charge.
• Significant regulatory and clinical milestones were achieved, including FDA approval for IDYSNSO for HIV-1 treatment and new data presented for its cardio-pulmonary pipeline.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed-to-positive result. While sales growth and raised outlook are positive, the significant net loss driven by acquisition costs and declines in some key products temper the overall sentiment.

Positives

• Worldwide sales increased by 5% to $16.3 billion in Q1 2026.
• KEYTRUDA/KEYTRUDA QLEX sales grew 12% to $8.0 billion.
• WINREVAIR sales showed substantial growth of 88% to $525 million.
• Animal Health sales increased by 13% to $1.8 billion.
• Full-year 2026 sales outlook was raised to $65.8 billion - $67.0 billion.
• Full-year 2026 non-GAAP EPS outlook was raised to $5.04 - $5.16.
• Received U.S. FDA approval for IDYSNSO, a new HIV-1 treatment.
• Presented positive Phase 3 data for its cardio-pulmonary pipeline.

Negatives

• Reported a GAAP loss per share of $1.72 and a non-GAAP loss per share of $1.28 for Q1 2026.
• Both GAAP and non-GAAP loss per share were heavily impacted by a $3.62 per share charge for the acquisition of Cidara.
• Sales of GARDASIL/GARDASIL 9 declined 19% due to lower demand in China and Japan.
• JANUVIA/JANUMET sales decreased by 28% due to generic competition and lower demand.
• LAGEVRIO sales dropped 73% due to lower demand.
• The outlook does not reflect the impact of the Terns Pharmaceuticals acquisition, which will result in a significant one-time charge.
• Phase 3 LITESPARK-012 and KEYNOTE-975 studies did not show statistically significant improvements in primary endpoints.
• Phase 3 KEYNOTE-866 study did not show a statistically significant improvement in EFS.

Risks

• General industry conditions and competition.
• General economic factors, including interest rate and currency exchange rate fluctuations.
• Impact of pharmaceutical industry regulation and health care legislation.
• Global trends toward health care cost containment.
• Technological advances, new products and patents attained by competitors.
• Challenges inherent in new product development, including obtaining regulatory approval.
• Manufacturing difficulties or delays.
• Financial instability of international economies and sovereign risk.

Future Outlook

Merck has narrowed and raised its full-year 2026 financial outlook, now expecting worldwide sales between $65.8 billion and $67.0 billion, and an expected non-GAAP EPS range between $5.04 and $5.16. This outlook does not include the impact of the proposed acquisition of Terns Pharmaceuticals, Inc., which is expected to close in May and result in a one-time charge of approximately $5.8 billion or $2.35 per share.

Management Comments

• "We are moving with speed to transform our portfolio to one with a diversified set of growth drivers across a broad set of therapeutic areas."
• "During the first quarter, we continued to strengthen our pipeline with science-led business development, including our planned acquisition of Terns."
• "We also achieved several important milestones, such as the FDA approval of IDVYNSO which marks a new chapter in our longstanding commitment to people living with HIV."
• "I am pleased with our progress and excited for whats ahead, as we enter a particularly robust period of Phase 3 data readouts and deliver on the promise of our pipeline for patients."

Industry Context

StockSavvy.ai notes that Merck's Q1 2026 results reflect continued strength in key therapeutic areas like oncology and animal health, alongside strategic business development moves such as the planned acquisition of Terns Pharmaceuticals. The company's ability to raise its full-year outlook amidst significant R&D investments and acquisition-related charges highlights its robust product portfolio and pipeline progression, a common theme among leading biopharmaceutical companies navigating a competitive and evolving market.

Comparison to Industry Standards

• Merck's oncology sales growth of 12% for KEYTRUDA/KEYTRUDA QLEX outpaces the average growth rates seen in many established oncology drugs within the industry, indicating strong market penetration and demand.
• The 88% growth for WINREVAIR demonstrates successful market entry and uptake, a significant achievement in a therapeutic area often characterized by slow adoption and high barriers to entry.
• The 13% growth in Animal Health sales aligns with broader industry trends showing sustained investment and innovation in veterinary medicine, driven by increased pet ownership and a focus on animal well-being.
• The significant increase in R&D expenses ($12.6 billion in Q1 2026 vs. $3.6 billion in Q1 2025) reflects a strategic commitment to pipeline development, a critical factor for long-term competitiveness in the biopharmaceutical sector, though the scale of the increase is notably driven by the Cidara acquisition.

Stakeholder Impact

• Shareholders: The raised full-year outlook and continued sales growth are positive indicators, but the significant net loss due to acquisition charges may impact short-term investor sentiment.
• Employees: The company's focus on pipeline development and strategic acquisitions suggests continued investment in innovation, potentially leading to future growth and opportunities.
• Patients: FDA approvals for IDYSNSO and advancements in oncology and cardio-pulmonary pipelines offer potential new treatment options and improved outcomes.
• Suppliers/Creditors: The company's strong sales performance and raised outlook suggest continued financial stability, supporting ongoing business relationships.

Next Steps

• Expected closing of the acquisition of Terns Pharmaceuticals, Inc. in May.
• Continued advancement of the pipeline with upcoming Phase 3 data readouts.
• Presentation of oncology strategy and program updates at the 2026 American Society of Clinical Oncology Annual Meeting on June 1, 2026.

Key Dates

Recommendation

Merck's Q1 2026 results present a mixed picture. While the company demonstrated solid sales growth in key areas like oncology and animal health, and raised its full-year guidance, the significant net loss due to acquisition-related charges and declines in certain product lines warrant caution. The strategic acquisitions and pipeline progress are positive long-term indicators, but the immediate financial impact of the Cidara acquisition and the lack of significant positive surprises in the results suggest a 'hold' recommendation until the market fully digests these factors and the integration of Terns Pharmaceuticals progresses.

Keywords

Merck, Q1 2026 Earnings, Pharmaceutical, Oncology, KEYTRUDA, Animal Health, Financial Results, SEC Filing